359 related articles for article (PubMed ID: 26490489)
1. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.
Zamagni E; Nanni C; Gay F; Pezzi A; Patriarca F; Bellò M; Rambaldi I; Tacchetti P; Hillengass J; Gamberi B; Pantani L; Magarotto V; Versari A; Offidani M; Zannetti B; Carobolante F; Balma M; Musto P; Rensi M; Mancuso K; Dimitrakopoulou-Strauss A; Chauviè S; Rocchi S; Fard N; Marzocchi G; Storto G; Ghedini P; Palumbo A; Fanti S; Cavo M
Leukemia; 2016 Feb; 30(2):417-22. PubMed ID: 26490489
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
[TBL] [Abstract][Full Text] [Related]
3. 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT.
Ho CL; Chen S; Leung YL; Cheng T; Wong KN; Cheung SK; Liang R; Chim CS
J Nucl Med; 2014 May; 55(5):749-52. PubMed ID: 24676754
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
5. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy.
Siontis B; Kumar S; Dispenzieri A; Drake MT; Lacy MQ; Buadi F; Dingli D; Kapoor P; Gonsalves W; Gertz MA; Rajkumar SV
Blood Cancer J; 2015 Oct; 5(10):e364. PubMed ID: 26495861
[TBL] [Abstract][Full Text] [Related]
7. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Nanni C; Zamagni E; Versari A; Chauvie S; Bianchi A; Rensi M; Bellò M; Rambaldi I; Gallamini A; Patriarca F; Gay F; Gamberi B; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):414-21. PubMed ID: 26475305
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
9. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C; Versari A; Chauvie S; Bertone E; Bianchi A; Rensi M; Bellò M; Gallamini A; Patriarca F; Gay F; Gamberi B; Ghedini P; Cavo M; Fanti S; Zamagni E
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):712-719. PubMed ID: 29270787
[TBL] [Abstract][Full Text] [Related]
10. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.
Ak İ; Onner H; Akay OM
Ann Hematol; 2015 Sep; 94(9):1567-75. PubMed ID: 26068066
[TBL] [Abstract][Full Text] [Related]
11. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
12. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using
Nakuz TS; Millinger FP; El-Rabadi K; Weber M; Pichler V; Wadsak W; Mitterhauser M; Haug A; Hacker M; Karanikas G; Pietschmann P; Agis H
Anticancer Res; 2019 Apr; 39(4):1943-1952. PubMed ID: 30952737
[TBL] [Abstract][Full Text] [Related]
14. Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma.
Elliott BM; Peti S; Osman K; Scigliano E; Lee D; Isola L; Kostakoglu L
Eur J Haematol; 2011 Apr; 86(4):289-98. PubMed ID: 21198866
[TBL] [Abstract][Full Text] [Related]
15. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
[TBL] [Abstract][Full Text] [Related]
18. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.
Hillengass J; Moulopoulos LA; Delorme S; Koutoulidis V; Mosebach J; Hielscher T; Drake M; Rajkumar SV; Oestergaard B; Abildgaard N; Hinge M; Plesner T; Suehara Y; Matsue K; Withofs N; Caers J; Waage A; Goldschmidt H; Dimopoulos MA; Lentzsch S; Durie B; Terpos E
Blood Cancer J; 2017 Aug; 7(8):e599. PubMed ID: 28841211
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.
Bhutani M; Turkbey B; Tan E; Korde N; Kwok M; Manasanch EE; Tageja N; Mailankody S; Roschewski M; Mulquin M; Carpenter A; Lamping E; Minter AR; Weiss BM; Mena E; Lindenberg L; Calvo KR; Maric I; Usmani SZ; Choyke PL; Kurdziel K; Landgren O
Leuk Lymphoma; 2016 May; 57(5):1114-21. PubMed ID: 26690712
[TBL] [Abstract][Full Text] [Related]
20. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
